SOUTH JERSEY
MEDICAL REPORT™

Clinical Trials

More than 450 clinical trials, including national trials, are currently underway at Cooper University Health Care, addressing a wide range of the latest pharmacologic, surgical, and device-related therapeutic options. Cooper's robust research program offers clinicians and their patients access to some of the most novel therapies and innovative trials in the region.

The following list represents some of the clinical trials currently enrolling patients at Cooper.

Study Area	Principal Investigator (PI)	Contact Info	Study Type	Study Description	Main Inclusion Criteria
Cardiology Arrhythmia/Implantable Defibrillator	Andrea M. Russo, MD	Claire F. Beeper 856.253.2361 Julie F. 856.669.8847	ICD Programming Study	The primary purpose of this study is to evaluate a subcutaneous ICD at specifically programmed settings.	1. Patient ≥21 years of age. 2. New patients undergoing a subcutaneous ICD System (S-ICD) for primary prevention. 3. Patients without spontaneous sustained VT or VF.
Cardiology Arrhythmia	Andrea M. Russo, MD	Claire F. Beeper 856.253.2361 Julie F. 856.669.8847	Treatment Study	Apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation.	1. Device-detected episode of SCAF >6 mins but <24 hours. 2. Must have at least one Stroke Risk Factor.
Cardiology Arrhythmia/Implantable Defibrillator	Andrea M. Russo, MD	Claire F. Beeper 856.253.2361 Julie F. 856.669.8847	ICD Education Study	The purpose of this study is to provide patients with information about an implantable cardioverter defibrillator device (ICD) that prevents sudden cardiac death (SCD), to learn more about what kind of information is helpful to patients in making treatment decisions with their doctors.	1. Patient >21 years of age. 2. Eligible for an implantable cardioverter defibrillator (ICD) for the primary prevention of sudden cardiac death. 3. Non-hospitalized patients with ejection fraction ≤35 percent.
Gynecologic Oncology Ovarian, fallopian tube, or primary peritoneal cancer	David P. Warshal, MD	Jackie T. 856.735.6396	Treatment Study	This study compares standard platinum-based chemotherapy to Olaparib as single-agent or in combination with Cediranib in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.	1. Female Patient >18 years of age. 2. Must have had a complete response to prior line of platinum therapy. 3. Patients who have no measurable disease following initial cytoreductive surgery and no evidence of disease progression for at least 6 months following their last platinum-based therapy or their date of surgery (whichever is later) are also eligible.
Hematology/Oncology Prostate	Ashish Patel, MD	Jackie T. 856.735.6396	Prospective Toxicity Evaluation & Quality of Life	This is a prospective evaluation of men undergoing stereotactic body radiation therapy (SBRT) for prostate cancer.	1. Males 18 years of age and older with low to intermediate risk prostate adenocarcinoma (T1-T2b, pretreatment PSA <10, Gleason sum 7 or less). 2. Patient must be a candidate for external beam radiation therapy (prior hormone therapy is allowed).
Hematology/Oncology Brain/Glioblastoma	Nati Lerman, MD	Jackie T. 856.735.6396	Treatment Study	This study evaluates concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma (GBM).	1. Patient >18 years of age. 2. Histologically confirmed de novo Grade IV glioma (GBM, gliosarcoma or other subvariants) confirmed by central pathology tissue screening.
Infectious Diseases HIV	Rosalie Pepe, MD	Dana O. 856.968.7008	Treatment Study	This study is testing the effects of statin-preventive therapy on vascular events in HIV patients not meeting 2013 ACC/AHA guideline thresholds for recommended statin initiation.	1. Patient ≥40 and ≤75 years of age. 2. CD4+ cell count >100 cells/mm3. 3. Fasting LDL cholesterol <190 mg/dL.
Infectious Diseases HIV	Katherine Doktor, MD	Dana O. 856.968.7008	Treatment Study	This study is to evaluate safety, tolerability, and efficacy of an injectable drug therapy on LDL-C in subjects with HIV and hyperlipidemia and/or mixed dyslipidemia.	1. Patient ≥18 years of age. 2. Subject on stable lipid-lowering therapy for ≥4 weeks prior to randomization. 3. Fasting triglycerides ≤600 mg/dL.
Neurology TIA or Minor Stroke	Thomas R. Mirsen, MD	Patricia N. 856.968.7269	Drug Study	This study evaluates the safety and efficacy of a drug therapy for prevention of reoccurring ischemic event.	1. Patient >18 years of age. 2. High risk TIA: or minor ischemic stroke.
Neurology Huntington's Disease	Amy Colcher, MD	Justin F. 856.682.2501	Drug Study	This study evaluates the safety and efficacy of drug therapy for Huntington's Disease.	1. Patient >18 years of age. 2. Huntington's Disease Stage I or II. 3. Ambulatory patients.
Neurology Parkinson's Disease	Andrew McGarry, MD	Amanda L. 856.968.7615	Drug Study	This study evaluates the efficacy of drug therapy for reduction of fatigue levels in patients with Parkinson's Disease.	1. Patient >18 years of age. 2. Diagnosis of Parkinson's Disease. 3. Significant levels of daytime fatigue.

Study Area	Principal Investigator (PI)	Contact Info	Study Type	Study Description	Main Inclusion Criteria
Neurosurgery Acute Spinal Cord Injury	Steven S. Yocom, DO	Justin F. 856.682.2501	Device Study	This study evaluates the safety and efficacy of a surgical device implanted in those with spinal cord injury.	1. Patient ≥16 and ≤70 years of age. 2. AIS A classification of traumatic spinal cord injury at spinal cord level T2 to T12/L1. 3. Non-penetrating SCI that is approximately 4 mm in diameter or greater.
Neurosurgery Acute Spinal Cord Injury	Steven S. Yocom, DO	Justin F. 856.682.2501	Drug Study	This study evaluates the safety and efficacy of drug therapy injections in adults with spinal cord injury.	1. Patient ≥ 14 and ≤75 years of age. 2. Acute traumatic cervical SCI, motor level of C4, C5, or C6 on each side. 3. AIS grade A or AIS grade B.
Orthopaedics Osteoarthritis	Lawrence S. Miller, MD	Justin F. 856.682.2501	Treatment Study	This study is to compare the safety and efficacy of using SVF cells derived from autologous adipose tissue to treat osteoarthritis of the knee.	1. Patient ≥40 and ≤75 years of age. 2. Must have grades II or III knee OA from KL-grade scale. 3. Having already tried two or more conservative therapies for relief: oral pain medications, physical therapy, corticosteroid injection of the knee, viscosupplementation injection of the knee.
Orthopaedics Bone Fractures	Douglas S. Tase, MD	Justin F. 856.682.2501	Registry	The American Orthopaedic Association's Own the Bone program is a national post-fracture, systems-based, multidisciplinary fragility fracture prevention initiative.	1. Patient with an osteoporotic fracture.
Trauma Surgery Necrotizing Infections	Ju-Lin Wang, MD	Janika S.R. 856.361.1324	Drug Study	This study evaluates treatment and outcomes for patients with surgery for necrotizing soft tissue infections.	1. Patient >18 years of age. 2. Clinical diagnosis of necrotizing soft tissue infections AND requires surgery for treatment.
Vascular Surgery AAA	Jose L. Trani, MD	Jonelle O. 856.342.2150	Device Study	This study evaluates the safety and efficacy of a polymer and endovascular graft combination in the treatment of abdominal aortic aneurysms (AAA).	1. Patient >18 years of age. 2. Must have an aneurysm/ulcer of the abdominal aorta.
Vascular Surgery AAA	Joseph V. Lombardi, MD	Jonelle O. 856.342.2150	Device Study	This study evaluates a thoracic branch device in the treatment of aneurysms of the aortic arch and descending thoracic aorta.	1. Patient >18 years of age. 2. Must have an aneurysm/ulcer of the thoracic aorta.

For more information about clinical trials at Cooper, please contact:

Barbara C. • Cooper Research Institute • 401 Haddon Avenue, Room 140 • Camden, NJ 08103 • P: 856.536.1030 • F: 856.536.1039